273 related articles for article (PubMed ID: 22251480)
1. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
Li Z; Huang H; Li Y; Jiang X; Chen P; Arnovitz S; Radmacher MD; Maharry K; Elkahloun A; Yang X; He C; He M; Zhang Z; Dohner K; Neilly MB; Price C; Lussier YA; Zhang Y; Larson RA; Le Beau MM; Caligiuri MA; Bullinger L; Valk PJ; Delwel R; Lowenberg B; Liu PP; Marcucci G; Bloomfield CD; Rowley JD; Chen J
Blood; 2012 Mar; 119(10):2314-24. PubMed ID: 22251480
[TBL] [Abstract][Full Text] [Related]
2. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
[TBL] [Abstract][Full Text] [Related]
3. Correlation of miR-181a and three HOXA genes as useful biomarkers in acute myeloid leukemia.
Xu P; Zhou D; Yan G; Ouyang J; Chen B
Int J Lab Hematol; 2020 Feb; 42(1):16-22. PubMed ID: 31670914
[TBL] [Abstract][Full Text] [Related]
4. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
5. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
[TBL] [Abstract][Full Text] [Related]
6. Long non‑coding RNA LINC00460 serves as a potential biomarker and oncogene via regulation of the miR‑320b/PBX3 axis in acute myeloid leukemia.
Zhuang Q; Jin Z; Zheng X; Jin T; Xiang L
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846790
[TBL] [Abstract][Full Text] [Related]
7. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.
Dickson GJ; Liberante FG; Kettyle LM; O'Hagan KA; Finnegan DP; Bullinger L; Geerts D; McMullin MF; Lappin TR; Mills KI; Thompson A
Haematologica; 2013 Aug; 98(8):1216-25. PubMed ID: 23539541
[TBL] [Abstract][Full Text] [Related]
8. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
9. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J
Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626
[TBL] [Abstract][Full Text] [Related]
11. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
[TBL] [Abstract][Full Text] [Related]
12. LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis.
Xiao S; Song B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32519740
[TBL] [Abstract][Full Text] [Related]
13. A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia.
Zhu R; Lin W; Zhao W; Fan F; Tang L; Hu Y
J Cell Biochem; 2019 Mar; 120(3):3958-3968. PubMed ID: 30242879
[TBL] [Abstract][Full Text] [Related]
14. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
15. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Whitman SP; Hickey C; Becker H; Metzeler KH; Paschka P; Baldus CD; Liu S; Garzon R; Powell BL; Kolitz JE; Carroll AJ; Caligiuri MA; Larson RA; Marcucci G; Bloomfield CD
J Clin Oncol; 2010 Dec; 28(36):5257-64. PubMed ID: 21079133
[TBL] [Abstract][Full Text] [Related]
17. CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.
Hájková H; Fritz MH; Haškovec C; Schwarz J; Šálek C; Marková J; Krejčík Z; Dostálová Merkerová M; Kostečka A; Vostrý M; Fuchs O; Michalová K; Cetkovský P; Beneš V
J Hematol Oncol; 2014 Sep; 7():66. PubMed ID: 25266220
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract][Full Text] [Related]
19. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
[TBL] [Abstract][Full Text] [Related]
20. A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia.
Zhu R; Zhao W; Fan F; Tang L; Liu J; Luo T; Deng J; Hu Y
Oncotarget; 2017 Jun; 8(24):38902-38913. PubMed ID: 28473658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
